- Hydresia(TM) G2 approved by leading European authority on natural/
organic certification -
TSX symbol: SBS
CALGARY, Oct. 6 /PRNewswire-FirstCall/ - Botaneco Specialty Ingredients Inc. (Botaneco), a subsidiary of SemBioSys Genetics Inc. (SemBioSys), today announced that its second generation oleosome product, Hydresia(TM) G2, has been authorized by ECOCERT(R) as an approved raw material, complying with the standards for ecological and organic cosmetics. ECOCERT(R) is one of the largest organic control and certification organizations in the world and conducts inspections in over 80 countries. The company's primary focus is food and food products, cosmetics, detergents, perfumes, and textiles.
"Botaneco is dedicated to manufacturing its all-natural products to comply with the highest natural production standards while eliminating the use of chemicals and synthetics," said Andrew Baum, president and CEO of Botaneco's parent company, SemBioSys. "The ECOCERT(R) authorization validates our product and production process with the most internationally recognized symbol for natural and organic raw materials."
Hydresia(TM) G2 is a cold-process emulsifying system comprised of oleosomes, naturally occurring oil reservoirs derived from safflower seeds. Oleosomes are nature's warehouse, or storage facility, for the emollient oils, antioxidants and natural moisture barriers that serve to keep the skin soft, supple and young looking. Using a proprietary non-solvent aqueous extraction process, these oleosomes are isolated from the seed fully intact, and when used in skin care applications can provide lasting protection to the skin. Hydresia(TM) G2 is a natural, renewable replacement for hydrocarbon derived petrolatum, mineral oil and non-ionic surfactants.
About Botaneco Specialty Ingredients Inc.
Botaneco is the global developer and marketer of innovative oleosome-based ingredients to the personal care and OTC topical markets. As a technologically driven provider of high performance, proprietary oleosome-based ingredients, Botaneco is committed to developing innovative ingredients that offer multifunctional, tangible and documented benefits to both formulators and consumers. Botaneco's head office and manufacturing facility is located in Calgary, Canada and its satellite office in Bensalem, PA. More information is available and can be accessed at http://www.botaneco.ca.
About SemBioSys Genetics Inc.
With headquarters in Calgary, Alberta, SemBioSys Genetics Inc. is a biotechnology company developing protein-based pharmaceuticals for metabolic and cardiovascular diseases. The Company's lead pharmaceutical candidates are recombinant human insulin to serve the rapidly expanding global diabetes market and Apo AI, a next generation cardiovascular drug. In addition to its pharmaceutical products, SemBioSys is developing a series of non-pharmaceutical products addressing animal and aquaculture health, nutritional oils and human topical markets. More information is available and can be accessed at http://www.sembiosys.com.
ECOCERT(R) is a control and certification organization, whose activities are governed accordingly by the public authorities and legislation. Based in Europe, ECOCERT(R) conducts inspections in over 80 countries and is accredited for structure and procedures by COFRAC (French committee for accreditation), in accordance with guide standard ISO 65 (EN 45011), which requires independence, competence and impartiality.
This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in the Company's ongoing filings with the Canadian securities regulatory authorities which filings can be found at http://www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.
|SOURCE SemBioSys Genetics Inc.|
Copyright©2008 PR Newswire.
All rights reserved